MX2020004271A - Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. - Google Patents

Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.

Info

Publication number
MX2020004271A
MX2020004271A MX2020004271A MX2020004271A MX2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A MX 2020004271 A MX2020004271 A MX 2020004271A
Authority
MX
Mexico
Prior art keywords
dpp3
epitopes
diseases
prevention
binding
Prior art date
Application number
MX2020004271A
Other languages
English (en)
Inventor
Andreas Bergmann
Original Assignee
4TEEN4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4TEEN4 Pharmaceuticals GmbH filed Critical 4TEEN4 Pharmaceuticals GmbH
Publication of MX2020004271A publication Critical patent/MX2020004271A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención provee un aglutinante dirigido a y que se une a una proteína DPP3 o derivados funcionales de la misma y su uso en un método de prevención o tratamiento de enfermedades o condiciones agudas en un paciente, en la cual dicha enfermedad o condición aguda está asociada con estrés oxidativo. Con este contexto, específicamente la presente invención provee un aglutinante que está dirigido a y que se une a un epítope de conformidad con SEQ ID NO.: 2, en el cual dicho epítope está comprendido en una proteína DPP3 o un derivado funcional de la misma, y en el cual dicho aglutinante de DPP3 reconoce a y se une a por lo menos tres aminoácidos de SEQ ID NO.: 2.
MX2020004271A 2017-10-25 2018-10-24 Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo. MX2020004271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198420 2017-10-25
PCT/EP2018/079197 WO2019081595A2 (en) 2017-10-25 2018-10-24 DPP3 BINDER DIRECTED TO AND BINDING SPECIFIC DPP3 EPITOPES AND USE THEREOF IN THE PREVENTION OR TREATMENT OF OXIDATIVE STRESS ASSOCIATED DISEASES / CONDITIONS

Publications (1)

Publication Number Publication Date
MX2020004271A true MX2020004271A (es) 2020-07-29

Family

ID=60186108

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004271A MX2020004271A (es) 2017-10-25 2018-10-24 Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.

Country Status (12)

Country Link
US (2) US11530276B2 (es)
EP (1) EP3700937A2 (es)
JP (2) JP7424972B2 (es)
KR (1) KR20200083509A (es)
CN (2) CN118791621A (es)
AU (1) AU2018356441A1 (es)
BR (1) BR112020006563A2 (es)
CA (1) CA3080251A1 (es)
IL (1) IL274009B1 (es)
MX (1) MX2020004271A (es)
SG (1) SG11202002594PA (es)
WO (1) WO2019081595A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP4121763A1 (en) 2020-03-16 2023-01-25 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6188884A (ja) 1984-10-04 1986-05-07 Sankyo Co Ltd エンケフアリナ−ゼｂ阻害物質およびその製法
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU6949200A (en) 1999-09-01 2001-03-26 Incyte Genomics, Inc. Human hydrolytic enzymes
MXPA04001804A (es) 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2005106486A2 (en) 2004-04-28 2005-11-10 Bayer Healthcare Ag Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
JP2006230318A (ja) 2005-02-25 2006-09-07 Maruishi Pharmaceutical Co Ltd 関節リウマチの診断方法
WO2007117444A2 (en) 2006-03-31 2007-10-18 Yinghe Hu Protein detection by aptamers
WO2007146229A2 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
RU2550258C2 (ru) 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
WO2010093872A2 (en) 2009-02-13 2010-08-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular-based method of cancer diagnosis and prognosis
WO2010113096A1 (en) * 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US9376477B2 (en) 2009-08-27 2016-06-28 Covagen Ag IL-17 binding compounds and medical uses thereof
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
DK2580236T3 (da) 2010-06-08 2019-06-11 Pieris Pharmaceuticals Gmbh Muteiner af tåre-lipocalin, der binder til il-4-r-alfa
CN105228633A (zh) 2013-01-28 2016-01-06 新天然替代品公司 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物
CN104946646B (zh) * 2014-03-25 2020-03-31 中国医学科学院基础医学研究所 用于预防和/或治疗埃博拉病毒性出血热的小核酸分子、dna分子、蛋白及应用
EP4417218A2 (en) 2016-04-21 2024-08-21 4TEEN4 Pharmaceuticals GmbH Methods for determining dpp3 and therapeutic methods

Also Published As

Publication number Publication date
CN118791621A (zh) 2024-10-18
JP7424972B2 (ja) 2024-01-30
RU2020116450A (ru) 2021-11-25
AU2018356441A1 (en) 2020-04-16
US20230295344A1 (en) 2023-09-21
EP3700937A2 (en) 2020-09-02
WO2019081595A4 (en) 2019-09-06
KR20200083509A (ko) 2020-07-08
SG11202002594PA (en) 2020-04-29
IL274009B1 (en) 2024-09-01
WO2019081595A3 (en) 2019-06-20
BR112020006563A2 (pt) 2020-10-13
US20210206876A1 (en) 2021-07-08
WO2019081595A2 (en) 2019-05-02
RU2020116450A3 (es) 2021-12-21
CN111542548A (zh) 2020-08-14
CA3080251A1 (en) 2019-05-02
IL274009A (en) 2020-05-31
US11530276B2 (en) 2022-12-20
CN111542548B (zh) 2024-07-30
JP2024041975A (ja) 2024-03-27
JP2021500376A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
IL277551A (en) Tri-specific binding molecules against cancer and their uses
MX2018013141A (es) Neurotoxinas quimericas.
PH12017502180A1 (en) Tau-binding antibodies
PH12016501644A1 (en) Binding proteins and methods of use thereof
MX2017002426A (es) Terapia de combinacion de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana.
IL272524A (en) CLEC9A binding factors and their use
IL273510A (en) Combined treatments and their use
ZA201906813B (en) Antibody binding specifically to muc1 and use thereof
MX2020004271A (es) Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.
PH12017502207A1 (en) Tau-binding antibodies
MX2019013537A (es) Compuestos para la prevencion y el tratamiento de enfermedades y el uso de los mismos.
IL278832A (en) Improved molecules that bind 41GP
MX359029B (es) Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -.
IL281114A (en) A new nuclease site and its use
IL271073A (en) b4galt1 variants and their uses
MX2018010683A (es) Compuestos de seleno-galactosida para la prevención y el tratamiento de las enfermedades asociadas con galectina y el uso de los mismos.
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
AU356758S (en) Brake drum cover
PL3430913T3 (pl) Kompozycja do wiązania mykotoksyn i jej zastosowanie
MX2017002277A (es) Anticuerpos que potencian el factor h y sus usos.
MX2017003020A (es) Compuestos de dipeptidil-cetoamida y su uso para el tratamiento y/o la prevencion de la acumulacion de grasa.
EP3636712C0 (en) FLUORORIC RUBBER COMPOSITION AND CROSS-LINKED FLUORORIC RUBBER PRODUCT
PL3728444T3 (pl) Spoiwa i powiązane produkty
SG11202008954UA (en) Novel promoter and use thereof
GB201815215D0 (en) Composition and use